ExeGi Pharma Secures License For Well-Studied Probiotic
GAITHERSBURG, Md., May 18, 2015 /PRNewswire-USNewswire/ -- ExeGi Pharma, a company focused on developing and commercializing live biotherapeutics and probiotic treatments, announced today that it has signed an agreement with Professor Claudio De Simone, MD, PhD, to produce a generic formulation of the probiotic marketed under the name "VSL#3®."
ExeGi Pharma will commercialize Visbiome and Visbiome Extra Strength, a generic formulation which will contain the same strains, in the same concentrations and proportions as the product tested and marketed under the brand name VSL#3®. It will be produced using the same manufacturing facility, methods and quality standards as the original product. The Visbiome formulation is a medical food that is intended for the dietary management of pouchitis, inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS).
"We couldn't be more pleased to work with Professor De Simone to launch Visbiome," said Marc Tewey, chief executive officer of ExeGi Pharma. "We know physicians depend on this formulation to manage challenging health conditions and our exclusive collaboration with Professor De Simone will ensure patients have continued access to the product they need."
"The microbiome is increasingly being understood by the larger scientific community as a major influencer in human health. It's critical that the formulation used in both clinical treatment and research settings maintains the highest product integrity," said Professor De Simone. "Researchers, physicians and patients can count on Visbiome to contain the formulation they have trusted for almost 15 years."
Visbiome will be available to physicians and patients starting in the summer of 2015. For more information, please visit www.exegipharma.com. ExeGi Pharma is headquartered in Gaithersburg.
About ExeGi Pharma
ExeGi Pharma LLC, is a biotechnology company focused on the development and commercialization of live biotherapeutic and probiotic medicines. ExeGi's team leverages scientific expertise in the field of microbiome science to deliver novel, clinically-supported live biotherapeutic and probiotic treatments for a variety of unmet medical needs. ExeGi is headquartered in Gaithersburg.
About Claudio De Simone
Claudio De Simone, MD, PhD, is an internationally recognized scientific leader in the field of probiotics and the human gut microflora. Professor De Simone invented the formulation of the probiotic tested and marketed under the name VSL#3®, which has been the subject of 60 clinical trials and is used for the dietary management of pouchitis, IBD and IBS. In addition, Professor De Simone has authored over 200 published scientific articles, reviews, case reports and book chapters.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/exegi-pharma-secures-license-for-well-studied-probiotic-300084818.html
SOURCE ExeGi Pharma